Entry Point Capital, LLC Cytokinetics Inc Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
403Shares Held
126MCall Options Held
3.27MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$819 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$639 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$454 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$419 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$366 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.26B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...